XML 24 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Goodwill and Other Intangible Assets
 9 Months Ended
Oct. 02, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets GOODWILL AND OTHER INTANGIBLE ASSETS
The following is a rollforward of the Company’s goodwill ($ in millions):
Balance, December 31, 2019$22,712.5 
Attributable to 2020 acquisitions10,301.4 
Attributable to 2020 divestitures(180.5)
Adjustments due to finalization of purchase price allocations(3.0)
Foreign currency translation and other1,439.3 
Balance, October 2, 2020$34,269.7 
The carrying value of goodwill by segment is summarized as follows ($ in millions):
October 2, 2020December 31, 2019
Life Sciences$24,866.5 $13,471.8 
Diagnostics6,951.6 6,901.2 
Environmental & Applied Solutions2,451.6 2,339.5 
Total$34,269.7 $22,712.5 
The increase in the goodwill balance of the Life Sciences segment in the nine-month period ended October 2, 2020 is a result of the Cytiva Acquisition. Measurement period adjustments since acquisition decreased the goodwill recognized for the Cytiva Acquisition by approximately $1.3 billion, as the initial allocation of the purchase price was adjusted to allocate additional purchase price to technology, customer relationships and trade names partially offset by related deferred tax liabilities. Refer to Note 3 for more detail. The Company has not identified any “triggering” events which indicate an impairment of goodwill in 2020.
Finite-lived intangible assets are amortized over their legal or estimated useful life. The following summarizes the gross carrying value and accumulated amortization for each major category of intangible assets ($ in millions):
October 2, 2020December 31, 2019
Gross Carrying AmountAccumulated AmortizationGross Carrying AmountAccumulated Amortization
Finite-lived intangibles:
Patents and technology$11,944.3 $(1,329.4)$2,712.7 $(934.1)
Customer relationships, trade names and other intangibles8,942.3 (3,013.3)6,367.4 (2,612.3)
Total finite-lived intangibles20,886.6 (4,342.7)9,080.1 (3,546.4)
Indefinite-lived intangibles:
Trademarks and trade names4,310.3 — 4,216.0 — 
Total intangibles$25,196.9 $(4,342.7)$13,296.1 $(3,546.4)
During the nine-month period ended October 2, 2020, the Company acquired finite-lived intangible assets, consisting primarily of developed technology, customer relationships and trade names, with a weighted average life of 17 years primarily as a result of the Cytiva Acquisition. Refer to Note 3 for additional information on the intangible assets acquired.
The Company identified impairment triggers during the first and third quarters of 2020 which resulted in the impairment of certain long-lived assets, including trade names and other intangible assets. The Company recorded impairment charges totaling $14 million and $22 million in the three and nine-month periods ended October 2, 2020, respectively, related to these long-lived assets.